These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3731917)

  • 1. Pharmacokinetics of metronidazole and its metabolites in reduced renal function.
    Bergan T; Thorsteinsson SB
    Chemotherapy; 1986; 32(4):305-18. PubMed ID: 3731917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of metronidazole and its major metabolite after a high intravenous dose.
    Bergan T; Aase S; Leinebo O; Harbitz T; Olsen A; Liavag I
    Scand J Gastroenterol Suppl; 1984; 91():113-23. PubMed ID: 6588488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of metronidazole in patients with varying degrees of renal failure.
    Houghton GW; Dennis MJ; Gabriel R
    Br J Clin Pharmacol; 1985 Feb; 19(2):203-9. PubMed ID: 3986078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronidazole: pharmacokinetic observations in severely ill patients.
    Ljungberg B; Nilsson-Ehle I; Ursing B
    J Antimicrob Chemother; 1984 Sep; 14(3):275-83. PubMed ID: 6490572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and bioavailability of metronidazole after tablets, suppositories and intravenous administration.
    Bergan T; Leinebo O; Blom-Hagen T; Salvesen B
    Scand J Gastroenterol Suppl; 1984; 91():45-60. PubMed ID: 6588489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration.
    Bergan T; Solhaug JH; Søreide O; Leinebø O
    Scand J Gastroenterol; 1985 Oct; 20(8):945-50. PubMed ID: 4081633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic activity of metronidazole in plasma and urine of volunteers with normal or impaired renal function.
    Turgeon PL; Dufresne LR; Ogilvie RI; Kreeft JH
    Surgery; 1983 Jan; 93(1 Pt 2):154-7. PubMed ID: 6849200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronidazole pharmacokinetics in patients with acute renal failure.
    Somogyi AA; Kong CB; Gurr FW; Sabto J; Spicer WJ; McLean AJ
    J Antimicrob Chemother; 1984 Feb; 13(2):183-9. PubMed ID: 6706889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of metronidazole and its metabolites in critically ill patients.
    Plaisance KI; Quintiliani R; Nightingale CH
    J Antimicrob Chemother; 1988 Feb; 21(2):195-200. PubMed ID: 3360682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics of metronidazole in Crohn's disease.
    Eradiri O; Jamali F; Thomson AB
    Biopharm Drug Dispos; 1987; 8(3):249-59. PubMed ID: 3593902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of metronidazole to tissues.
    Holter O; Bergan T; Flørenes T; Leinebø O
    J Antimicrob Chemother; 1983 Apr; 11(4):357-60. PubMed ID: 6853405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of metronidazole in patients with enteric disease compared to normal volunteers.
    Bergan T; Bjerke PE; Fausa O
    Chemotherapy; 1981; 27(4):233-8. PubMed ID: 7249785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition and metabolism of metronidazole in patients with liver failure.
    Farrell G; Baird-Lambert J; Cvejic M; Buchanan N
    Hepatology; 1984; 4(4):722-6. PubMed ID: 6745863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function.
    Prescott LF; Freestone S; McAuslane JA
    Br J Clin Pharmacol; 1993 Jan; 35(1):20-9. PubMed ID: 8448064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of metronidazole in healthy adult volunteers after tablets and suppositories.
    Bergan T; Arnold E
    Chemotherapy; 1980; 26(4):231-41. PubMed ID: 7389423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis.
    Gambertoglio JG; Alexander DP; Barriere SL
    Antimicrob Agents Chemother; 1984 Dec; 26(6):845-9. PubMed ID: 6098220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between pharmacokinetics and bioavailability of cefroxadine (CGP 9000) and renal function.
    Bergan T; Brodwall EK; Larsen EW
    Chemotherapy; 1983; 29(3):163-73. PubMed ID: 6872614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of spectinomycin in volunteers with renal insufficiency.
    Kusumi R; Metzler C; Fass R
    Chemotherapy; 1981; 27(2):95-8. PubMed ID: 6451365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.